EHA 2022 Highlights

CME

CCO Independent Conference Highlights of the European Hematology Association 2022 Congress

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 06, 2022

Expiration: September 05, 2023

Stéphane de Botton
Stéphane de Botton, MD
Jesús F. San-Miguel
Jesús F. San-Miguel, MD, PhD
Alessandra Tedeschi
Alessandra Tedeschi, MD

Activity

Progress
1
Course Completed

At the European Hematology Association (EHA) 2022 Congress in Vienna, Austria, new clinical trial data were reported for numerous hematologic malignancies. In this module, Alessandra Tedeschi, MD; Stéphane de Botton, MD; and Jesús F. San-Miguel, MD, PhD, review and discuss the clinical implications of key studies in acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), multiple myeloma, myelodysplastic syndromes (MDS), and Waldenström macroglobulinemia.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with hematologic malignancies do you provide care for in a typical month?

When discussing acalabrutinib treatment for your patients with CLL, which of the following adverse events (AEs) would you tell them they are less likely to experience with this drug compared with chemoimmunotherapy based on clinical trial data?

When discussing investigational therapy options for a patient with heavily pretreated relapsed/refractory FL, which of the following results would you identify as shown with zanubrutinib plus obinutuzumab compared with obinutuzumab monotherapy in the ongoing randomized phase II ROSEWOOD trial?

Which of the following would you discuss as a potential investigational therapy for a patient diagnosed with high-risk MDS?

Which of the following is the second antigen targeted by the CD3-directed bispecific antibody teclistamab?